APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Liposome Drug Delivery

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Selected research

Market Outlook & Growth Opportunities

Global Liposome Drug Delivery Market Outlook and Growth Opportunities 2026

Report ID 17400803049 January 2026195 pages

Choose your research edition.

Industry ResearchLiposome Drug Delivery Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposome Drug Delivery Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Liposome Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposome Drug Delivery Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposome Drug Delivery Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.

This report provides an overview of the global Liposome Drug Delivery market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Liposome Drug Delivery and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liposome Drug Delivery sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liposome Drug Delivery market size, projected growth trends, production technologies, key applications, and end-use industries.

Liposome Drug Delivery Segment by Company

Gilead Sciences

Pacira

Sun Pharmaceutical

Johnson & Johnson

Luye Pharma

Sigma-Tau

Ipsen (Onivyde)

CSPC

Teva Pharmaceutical

Novartis

Fudan-Zhangjiang

Liposome Drug Delivery Segment by Type

Liposomal Doxorubicin

Liposomal Amphoteracin B

Liposomal Paclitaxel

Others

Liposome Drug Delivery Segment by Application

Fungal Infection Therapy

Cancer & Tumor Therapy

Others

Liposome Drug Delivery Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Liposome Drug Delivery status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liposome Drug Delivery market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liposome Drug Delivery significant trends, drivers, influence factors in global and regions.

6. To analyze Liposome Drug Delivery competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposome Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposome Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposome Drug Delivery.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liposome Drug Delivery market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liposome Drug Delivery industry.

Chapter 3: Detailed analysis of Liposome Drug Delivery manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liposome Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liposome Drug Delivery in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liposome Drug Delivery Industry Trends Table 2. Liposome Drug Delivery Industry Drivers Table 3. Liposome Drug Delivery Industry Opportunities and Challenges Table 4. Liposome Drug Delivery Industry Restraints Table 5. Global Liposome Drug Delivery Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liposome Drug Delivery Revenue Share by Company (2021-2026) Table 7. Global Liposome Drug Delivery Sales Volume by Company (K Vial) & (2021-2026) Table 8. Global Liposome Drug Delivery Sales Volume Share by Company (2021-2026) Table 9. Global Liposome Drug Delivery Average Price (USD/Vial) of Company (2021-2026) Table 10. Global Liposome Drug Delivery Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liposome Drug Delivery Key Company Manufacturing Base & Headquarters Table 12. Global Liposome Drug Delivery Company, Product Type & Application Table 13. Global Liposome Drug Delivery Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liposome Drug Delivery by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Liposomal Doxorubicin Table 18. Significant Companies of Liposomal Amphoteracin B Table 19. Significant Companies of Liposomal Paclitaxel Table 20. Significant Companies of Others Table 21. Global Liposome Drug Delivery Sales Volume by Type 2021 VS 2025 VS 2032 (K Vial) Table 22. Global Liposome Drug Delivery Sales Volume by Type (2021-2026) & (K Vial) Table 23. Global Liposome Drug Delivery Sales Volume by Type (2027-2032) & (K Vial) Table 24. Global Liposome Drug Delivery Sales Volume Share by Type (2021-2026) Table 25. Global Liposome Drug Delivery Sales Volume Share by Type (2027-2032) Table 26. Global Liposome Drug Delivery Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Liposome Drug Delivery Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Liposome Drug Delivery Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Liposome Drug Delivery Sales Value Share by Type (2021-2026) Table 30. Global Liposome Drug Delivery Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Fungal Infection Therapy Table 32. Significant Companies of Cancer & Tumor Therapy Table 33. Significant Companies of Others Table 34. Global Liposome Drug Delivery Sales Volume by Application 2021 VS 2025 VS 2032 (K Vial) Table 35. Global Liposome Drug Delivery Sales Volume by Application (2021-2026) & (K Vial) Table 36. Global Liposome Drug Delivery Sales Volume by Application (2027-2032) & (K Vial) Table 37. Global Liposome Drug Delivery Sales Volume Share by Application (2021-2026) Table 38. Global Liposome Drug Delivery Sales Volume Share by Application (2027-2032) Table 39. Global Liposome Drug Delivery Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Liposome Drug Delivery Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Liposome Drug Delivery Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Liposome Drug Delivery Sales Value Share by Application (2021-2026) Table 43. Global Liposome Drug Delivery Sales Value Share by Application (2027-2032) Table 44. Global Liposome Drug Delivery Sales by Region: 2021 VS 2025 VS 2032 (K Vial) Table 45. Global Liposome Drug Delivery Sales by Region (2021-2026) & (K Vial) Table 46. Global Liposome Drug Delivery Sales Market Share by Region (2021-2026) Table 47. Global Liposome Drug Delivery Sales by Region (2027-2032) & (K Vial) Table 48. Global Liposome Drug Delivery Sales Market Share by Region (2027-2032) Table 49. Global Liposome Drug Delivery Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Liposome Drug Delivery Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Liposome Drug Delivery Sales Value Share by Region (2021-2026) Table 52. Global Liposome Drug Delivery Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Liposome Drug Delivery Sales Value Share by Region (2027-2032) Table 54. Global Liposome Drug Delivery Market Average Price (USD/Vial) by Region (2021-2026) Table 55. Global Liposome Drug Delivery Market Average Price (USD/Vial) by Region (2027-2032) Table 56. Global Liposome Drug Delivery Sales by Country: 2021 VS 2025 VS 2032 (K Vial) Table 57. Global Liposome Drug Delivery Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Liposome Drug Delivery Sales by Country (2021-2026) & (K Vial) Table 59. Global Liposome Drug Delivery Sales Market Share by Country (2021-2026) Table 60. Global Liposome Drug Delivery Sales by Country (2027-2032) & (K Vial) Table 61. Global Liposome Drug Delivery Sales Market Share by Country (2027-2032) Table 62. Global Liposome Drug Delivery Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Liposome Drug Delivery Sales Value Market Share by Country (2021-2026) Table 64. Global Liposome Drug Delivery Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Liposome Drug Delivery Sales Value Market Share by Country (2027-2032) Table 66. Gilead Sciences Company Information Table 67. Gilead Sciences Business Overview Table 68. Gilead Sciences Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 69. Gilead Sciences Liposome Drug Delivery Product Portfolio Table 70. Gilead Sciences Recent Development Table 71. Pacira Company Information Table 72. Pacira Business Overview Table 73. Pacira Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 74. Pacira Liposome Drug Delivery Product Portfolio Table 75. Pacira Recent Development Table 76. Sun Pharmaceutical Company Information Table 77. Sun Pharmaceutical Business Overview Table 78. Sun Pharmaceutical Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 79. Sun Pharmaceutical Liposome Drug Delivery Product Portfolio Table 80. Sun Pharmaceutical Recent Development Table 81. Johnson & Johnson Company Information Table 82. Johnson & Johnson Business Overview Table 83. Johnson & Johnson Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 84. Johnson & Johnson Liposome Drug Delivery Product Portfolio Table 85. Johnson & Johnson Recent Development Table 86. Luye Pharma Company Information Table 87. Luye Pharma Business Overview Table 88. Luye Pharma Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 89. Luye Pharma Liposome Drug Delivery Product Portfolio Table 90. Luye Pharma Recent Development Table 91. Sigma-Tau Company Information Table 92. Sigma-Tau Business Overview Table 93. Sigma-Tau Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 94. Sigma-Tau Liposome Drug Delivery Product Portfolio Table 95. Sigma-Tau Recent Development Table 96. Ipsen (Onivyde) Company Information Table 97. Ipsen (Onivyde) Business Overview Table 98. Ipsen (Onivyde) Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 99. Ipsen (Onivyde) Liposome Drug Delivery Product Portfolio Table 100. Ipsen (Onivyde) Recent Development Table 101. CSPC Company Information Table 102. CSPC Business Overview Table 103. CSPC Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 104. CSPC Liposome Drug Delivery Product Portfolio Table 105. CSPC Recent Development Table 106. Teva Pharmaceutical Company Information Table 107. Teva Pharmaceutical Business Overview Table 108. Teva Pharmaceutical Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 109. Teva Pharmaceutical Liposome Drug Delivery Product Portfolio Table 110. Teva Pharmaceutical Recent Development Table 111. Novartis Company Information Table 112. Novartis Business Overview Table 113. Novartis Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 114. Novartis Liposome Drug Delivery Product Portfolio Table 115. Novartis Recent Development Table 116. Fudan-Zhangjiang Company Information Table 117. Fudan-Zhangjiang Business Overview Table 118. Fudan-Zhangjiang Liposome Drug Delivery Sales (K Vial), Value (US$ Million), Price (USD/Vial) and Gross Margin (2021-2026) Table 119. Fudan-Zhangjiang Liposome Drug Delivery Product Portfolio Table 120. Fudan-Zhangjiang Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Liposome Drug Delivery Distributors List Table 124. Liposome Drug Delivery Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Liposome Drug Delivery Product Image Figure 2. Global Liposome Drug Delivery Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposome Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liposome Drug Delivery Sales (2021-2032) & (K Vial) Figure 5. Global Liposome Drug Delivery Sales Average Price (USD/Vial) & (2021-2032) Figure 6. Global Liposome Drug Delivery Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Liposomal Doxorubicin Image Figure 10. Liposomal Amphoteracin B Image Figure 11. Liposomal Paclitaxel Image Figure 12. Others Image Figure 13. Global Liposome Drug Delivery Sales Volume by Type (2021 VS 2025 VS 2032) & (K Vial) Figure 14. Global Liposome Drug Delivery Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Liposome Drug Delivery Sales Volume Share by Type (2021-2032) Figure 16. Global Liposome Drug Delivery Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Liposome Drug Delivery Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Liposome Drug Delivery Sales Value Share by Type (2021-2032) Figure 19. Fungal Infection Therapy Image Figure 20. Cancer & Tumor Therapy Image Figure 21. Others Image Figure 22. Global Liposome Drug Delivery Sales Volume by Application (2021 VS 2025 VS 2032) & (K Vial) Figure 23. Global Liposome Drug Delivery Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Liposome Drug Delivery Sales Volume Share by Application (2021-2032) Figure 25. Global Liposome Drug Delivery Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Liposome Drug Delivery Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Liposome Drug Delivery Sales Value Share by Application (2021-2032) Figure 28. Global Liposome Drug Delivery Sales by Region: 2021 VS 2025 VS 2032 (K Vial) Figure 29. Global Liposome Drug Delivery Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Liposome Drug Delivery Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Liposome Drug Delivery Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Liposome Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 33. North America Liposome Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Liposome Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Liposome Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Liposome Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Liposome Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Liposome Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 39. South America Liposome Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Liposome Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Liposome Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Liposome Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Liposome Drug Delivery Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Liposome Drug Delivery Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomal Doxorubicin
  • Liposomal Amphoteracin B
  • Liposomal Paclitaxel
  • Others
Applications
  • Fungal Infection Therapy
  • Cancer & Tumor Therapy
  • Others
Companies covered
  • Gilead Sciences
  • Pacira
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Luye Pharma
  • Sigma-Tau
  • Ipsen (Onivyde)
  • CSPC
  • Teva Pharmaceutical
  • Novartis
  • Fudan-Zhangjiang

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liposome Drug Delivery Sales Value (2021-2032)
  4. 1.2.2 Global Liposome Drug Delivery Sales Volume (2021-2032)
  5. 1.2.3 Global Liposome Drug Delivery Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liposome Drug Delivery Market Dynamics
  1. 2.1 Liposome Drug Delivery Industry Trends
  2. 2.2 Liposome Drug Delivery Industry Drivers
  3. 2.3 Liposome Drug Delivery Industry Opportunities and Challenges
  4. 2.4 Liposome Drug Delivery Industry Restraints
3 Liposome Drug Delivery Market by Company
  1. 3.1 Global Liposome Drug Delivery Company Revenue Ranking in 2025
  2. 3.2 Global Liposome Drug Delivery Revenue by Company (2021-2026)
  3. 3.3 Global Liposome Drug Delivery Sales Volume by Company (2021-2026)
  4. 3.4 Global Liposome Drug Delivery Average Price by Company (2021-2026)
  5. 3.5 Global Liposome Drug Delivery Company Ranking (2024-2026)
  6. 3.6 Global Liposome Drug Delivery Company Manufacturing Base and Headquarters
  7. 3.7 Global Liposome Drug Delivery Company Product Type and Application
  8. 3.8 Global Liposome Drug Delivery Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liposome Drug Delivery Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liposome Drug Delivery Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liposome Drug Delivery Market by Type
  1. 4.1 Liposome Drug Delivery Type Introduction
  2. 4.1.1 Liposomal Doxorubicin
  3. 4.1.2 Liposomal Amphoteracin B
  4. 4.1.3 Liposomal Paclitaxel
  5. 4.1.4 Others
  6. 4.2 Global Liposome Drug Delivery Sales Volume by Type
  7. 4.2.1 Global Liposome Drug Delivery Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Liposome Drug Delivery Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Liposome Drug Delivery Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Liposome Drug Delivery Sales Value by Type
  11. 4.3.1 Global Liposome Drug Delivery Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Liposome Drug Delivery Sales Value by Type (2021-2032)
  13. 4.3.3 Global Liposome Drug Delivery Sales Value Share by Type (2021-2032)
5 Liposome Drug Delivery Market by Application
  1. 5.1 Liposome Drug Delivery Application Introduction
  2. 5.1.1 Fungal Infection Therapy
  3. 5.1.2 Cancer & Tumor Therapy
  4. 5.1.3 Others
  5. 5.2 Global Liposome Drug Delivery Sales Volume by Application
  6. 5.2.1 Global Liposome Drug Delivery Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liposome Drug Delivery Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Liposome Drug Delivery Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Liposome Drug Delivery Sales Value by Application
  10. 5.3.1 Global Liposome Drug Delivery Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Liposome Drug Delivery Sales Value by Application (2021-2032)
  12. 5.3.3 Global Liposome Drug Delivery Sales Value Share by Application (2021-2032)
6 Liposome Drug Delivery Regional Sales and Value Analysis
  1. 6.1 Global Liposome Drug Delivery Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liposome Drug Delivery Sales by Region (2021-2032)
  3. 6.2.1 Global Liposome Drug Delivery Sales by Region: 2021-2026
  4. 6.2.2 Global Liposome Drug Delivery Sales by Region (2027-2032)
  5. 6.3 Global Liposome Drug Delivery Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liposome Drug Delivery Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liposome Drug Delivery Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liposome Drug Delivery Sales Value by Region (2027-2032)
  9. 6.5 Global Liposome Drug Delivery Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liposome Drug Delivery Sales Value (2021-2032)
  12. 6.6.2 North America Liposome Drug Delivery Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liposome Drug Delivery Sales Value (2021-2032)
  15. 6.7.2 Europe Liposome Drug Delivery Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liposome Drug Delivery Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liposome Drug Delivery Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liposome Drug Delivery Sales Value (2021-2032)
  21. 6.9.2 South America Liposome Drug Delivery Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liposome Drug Delivery Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liposome Drug Delivery Sales Value Share by Country, 2025 VS 2032
7 Liposome Drug Delivery Country-level Sales and Value Analysis
  1. 7.1 Global Liposome Drug Delivery Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liposome Drug Delivery Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liposome Drug Delivery Sales by Country (2021-2032)
  4. 7.3.1 Global Liposome Drug Delivery Sales by Country (2021-2026)
  5. 7.3.2 Global Liposome Drug Delivery Sales by Country (2027-2032)
  6. 7.4 Global Liposome Drug Delivery Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liposome Drug Delivery Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liposome Drug Delivery Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liposome Drug Delivery Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liposome Drug Delivery Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liposome Drug Delivery Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences Liposome Drug Delivery Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 Pacira
  8. 8.2.1 Pacira Company Information
  9. 8.2.2 Pacira Business Overview
  10. 8.2.3 Pacira Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pacira Liposome Drug Delivery Product Portfolio
  12. 8.2.5 Pacira Recent Developments
  13. 8.3 Sun Pharmaceutical
  14. 8.3.1 Sun Pharmaceutical Company Information
  15. 8.3.2 Sun Pharmaceutical Business Overview
  16. 8.3.3 Sun Pharmaceutical Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Liposome Drug Delivery Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Liposome Drug Delivery Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Luye Pharma
  26. 8.5.1 Luye Pharma Company Information
  27. 8.5.2 Luye Pharma Business Overview
  28. 8.5.3 Luye Pharma Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Luye Pharma Liposome Drug Delivery Product Portfolio
  30. 8.5.5 Luye Pharma Recent Developments
  31. 8.6 Sigma-Tau
  32. 8.6.1 Sigma-Tau Company Information
  33. 8.6.2 Sigma-Tau Business Overview
  34. 8.6.3 Sigma-Tau Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sigma-Tau Liposome Drug Delivery Product Portfolio
  36. 8.6.5 Sigma-Tau Recent Developments
  37. 8.7 Ipsen (Onivyde)
  38. 8.7.1 Ipsen (Onivyde) Company Information
  39. 8.7.2 Ipsen (Onivyde) Business Overview
  40. 8.7.3 Ipsen (Onivyde) Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Ipsen (Onivyde) Liposome Drug Delivery Product Portfolio
  42. 8.7.5 Ipsen (Onivyde) Recent Developments
  43. 8.8 CSPC
  44. 8.8.1 CSPC Company Information
  45. 8.8.2 CSPC Business Overview
  46. 8.8.3 CSPC Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CSPC Liposome Drug Delivery Product Portfolio
  48. 8.8.5 CSPC Recent Developments
  49. 8.9 Teva Pharmaceutical
  50. 8.9.1 Teva Pharmaceutical Company Information
  51. 8.9.2 Teva Pharmaceutical Business Overview
  52. 8.9.3 Teva Pharmaceutical Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Teva Pharmaceutical Liposome Drug Delivery Product Portfolio
  54. 8.9.5 Teva Pharmaceutical Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Liposome Drug Delivery Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Fudan-Zhangjiang
  62. 8.11.1 Fudan-Zhangjiang Company Information
  63. 8.11.2 Fudan-Zhangjiang Business Overview
  64. 8.11.3 Fudan-Zhangjiang Liposome Drug Delivery Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Fudan-Zhangjiang Liposome Drug Delivery Product Portfolio
  66. 8.11.5 Fudan-Zhangjiang Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liposome Drug Delivery Value Chain Analysis
  2. 9.1.1 Liposome Drug Delivery Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liposome Drug Delivery Sales Mode & Process
  6. 9.2 Liposome Drug Delivery Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liposome Drug Delivery Distributors
  9. 9.2.3 Liposome Drug Delivery Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst